title: The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant.
abstract: The HIV-1 matrix protein p17 is a structural protein essential in the life cycle of HIV, by acting as a virokine/immunomodulator that supports viral replication and spreading. The presence of p17-specific antibodies and CTL responses correlates with slower progression to AIDS. Intranasal vaccination with p17 and the TLR2/6 agonist MALP-2 stimulates strong humoral and cellular immune responses at systemic and mucosal levels. The antibodies blocked p17 binding to its receptor, which is a critical step for the exertion of its virokine activity. Our results suggest that p17 and MALP-2 are attractive candidates for incorporation in mucosal vaccines against HIV/AIDS.
authors.affiliation: Department of Vaccinology, GBF-German Research Centre for Biotechnology, Mascheroder Weg 1, D-38124 Braunschweig, Germany.
authors.forename: Pablo D
authors.initials: PD
authors.lastname: Becker
authors.forename: Simona
authors.initials: S
authors.lastname: Fiorentini
authors.forename: Claudia
authors.initials: C
authors.lastname: Link
authors.forename: Giorgio
authors.initials: G
authors.lastname: Tosti
authors.forename: Thomas
authors.initials: T
authors.lastname: Ebensen
authors.forename: Arnaldo
authors.initials: A
authors.lastname: Caruso
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Guzmán
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000281:Administration, Intranasal; D000818:Animals; D005260:Female; D015683:Gene Products, gag / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D015483:HIV Antibodies / Q000097:blood / Q000378:metabolism; D015488:HIV Antigens / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal; D007071:Immunoglobulin A, Secretory / Q000378:metabolism; D007074:Immunoglobulin G / Q000097:blood; D055666:Lipopeptides; D051379:Mice; D008807:Mice, Inbred BALB C; D009842:Oligopeptides / Q000008:administration & dosage* / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D051195:Toll-Like Receptor 2; D014764:Viral Proteins / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D015683:Gene Products, gag; D015483:HIV Antibodies; D015488:HIV Antigens; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G; D055666:Lipopeptides; D009842:Oligopeptides; D051195:Toll-Like Receptor 2; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1; C106335:macrophage stimulatory lipopeptide 2